Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.
(205) 975-3914

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences. Also has beats in biochemistry, cell biology, microbiology, pathology, the Alabama Drug Discovery Alliance and the Institute for Innovation and Entrepreneurship.
Improvements in motor function and memory suggest human neurodevelopmental disorders may be amenable to treatment, even after onset of symptoms. According to a researcher, neurodevelopmental disorders with intellectual disability and autism may not need to last a lifetime.
This potential chemotherapeutic agent to treat glioblastoma — a primary brain tumor with dismal survival rates — is a novel small molecule inhibitor.
This novel method improves purification of complex proteins by 10- to 500-fold, and it may aid both research and large-scale industrial production.
This active drug-delivery system addresses the limitations seen for the anti-cancer drug BA-TPQ — poor solubility and low bioavailability.
The goal is to avoid unnecessary surgery and reduce the number of biopsies of benign nodules and cancers that are unlikely to cause harm.
This type of lab course is part of a national undergraduate biology education reform effort.
This is the first demonstration of donor microbes persisting in the recipient following fecal transplant, a finding made possible by a novel method to “fingerprint” individual strains of bacteria.
Allostery, a fundamental means of regulating enzymes, is crucial for living cells.
A biomarker, endothelial mitochondrial function, may be useful for early identification of newborn babies at risk for lung disease and could enable novel therapy approaches.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
Page 1 of 13
Back to Top